FDA delay could help Neoprobe boost cancer drug’s price
A delay in the regulatory approval process for Neoprobe Corp.'s (OTCBB:NEOP) cancer drug could have the effect of helping the company increase the drug's price once it's commercialized.
Neoprobe files for listing on NYSE: Amex market
Device and drugmaker Neoprobe Inc. (OTCBB: NEOP) has applied for listing on the NYSE: Amex market. The move would make the Dublin, Ohio, company more attractive to institutional investors and provide more liquidity for existing investors, according to a statement from the company. Neoprobe is currently traded on Nasdaq’s Over-The-Counter Bulletin Board. CEO David Bupp […]
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Neoprobe to file for FDA approval of Lymphoseek this summer
Neoprobe Corp. is looking to file for regulatory approval of its cancer-detection drug Lymphoseek this summer. The company seems optimistic about Lymphoseek’s prospects after the “positive outcome” of a meeting with the U.S. Food and Drug Administration, Chief Executive David Bupp said in a statement announcing the company’s first-quarter financial results. Receiving FDA approval for […]